[go: up one dir, main page]

AR048775A1 - Un medicamento que comprende ptx3 y un agente antifungico para el tratamiento de infecciones fungicas particularmente aspergilosis - Google Patents

Un medicamento que comprende ptx3 y un agente antifungico para el tratamiento de infecciones fungicas particularmente aspergilosis

Info

Publication number
AR048775A1
AR048775A1 ARP050101819A ARP050101819A AR048775A1 AR 048775 A1 AR048775 A1 AR 048775A1 AR P050101819 A ARP050101819 A AR P050101819A AR P050101819 A ARP050101819 A AR P050101819A AR 048775 A1 AR048775 A1 AR 048775A1
Authority
AR
Argentina
Prior art keywords
infections
treatment
ptx3
aspergylosis
fungical
Prior art date
Application number
ARP050101819A
Other languages
English (en)
Inventor
Giovanni Salvatori
Paolo Carminati
Luigina Romani
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of AR048775A1 publication Critical patent/AR048775A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se describe la combinacion de pentraxina PTX3 con antifungicos para el tratamiento de infecciones fungicas y particularmente para infecciones provocadas por Aspergillus fumigatus.
ARP050101819A 2004-05-07 2005-05-05 Un medicamento que comprende ptx3 y un agente antifungico para el tratamiento de infecciones fungicas particularmente aspergilosis AR048775A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000223A ITRM20040223A1 (it) 2004-05-07 2004-05-07 Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi.

Publications (1)

Publication Number Publication Date
AR048775A1 true AR048775A1 (es) 2006-05-24

Family

ID=34968212

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101819A AR048775A1 (es) 2004-05-07 2005-05-05 Un medicamento que comprende ptx3 y un agente antifungico para el tratamiento de infecciones fungicas particularmente aspergilosis

Country Status (24)

Country Link
US (2) US8778389B2 (es)
EP (1) EP1750744B1 (es)
JP (1) JP5574565B2 (es)
KR (1) KR101192611B1 (es)
CN (1) CN1950104B (es)
AR (1) AR048775A1 (es)
AT (1) ATE397937T1 (es)
AU (1) AU2005239913B2 (es)
BR (1) BRPI0510718A (es)
CA (1) CA2563400C (es)
CY (1) CY1108332T1 (es)
DE (1) DE602005007485D1 (es)
DK (1) DK1750744T3 (es)
ES (1) ES2306145T3 (es)
HR (1) HRP20080413T3 (es)
IT (1) ITRM20040223A1 (es)
ME (1) ME02743B (es)
MX (1) MXPA06012889A (es)
PL (1) PL1750744T3 (es)
PT (1) PT1750744E (es)
RS (1) RS50591B (es)
SI (1) SI1750744T1 (es)
TW (1) TWI393569B (es)
WO (1) WO2005107791A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040489A1 (it) * 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
ITMI20062448A1 (it) * 2006-12-19 2008-06-20 Univ Degli Studi Modena E Reggio Emilia Metodo per la diagnosi e/o il monitoraggio dell¿ aspergillosi invasiva
US8838152B2 (en) 2007-11-30 2014-09-16 Microsoft Corporation Modifying mobile device operation using proximity relationships
CN101280326B (zh) * 2008-05-14 2011-07-06 中国科学院微生物研究所 一种抑制烟曲霉活性的化合物制备方法及其应用
WO2013191280A1 (ja) * 2012-06-22 2013-12-27 国立大学法人 東京大学 全身性炎症反応症候群の治療又は予防剤
CN112334773A (zh) * 2018-06-01 2021-02-05 B.R.A.H.M.S有限公司 用于诊断侵袭性真菌感染的生物标记物
EP3669885A1 (en) * 2018-12-20 2020-06-24 Humanitas Mirasole S.p.A. Use of sap for the treatment of eurotiomycetes fungi infections
CN113952401B (zh) * 2021-12-15 2022-10-25 河北农业大学 一种用于防治畜禽曲霉菌感染的中药及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
AU598958B2 (en) * 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
JP2001183375A (ja) 1999-12-27 2001-07-06 Tosoh Corp 酵素標識抗体
US20050187161A1 (en) * 2003-09-12 2005-08-25 Board Of Regents, The University Of Texas System Biopanning as an approach to study the pathogenesis of and produce novel treatment modalities for invasive Aspergillosis
CA2560931A1 (en) * 2004-03-29 2005-10-06 The University Of Mississippi Novel cyclopentenedione antifungal compounds and methods for their use
ITRM20040489A1 (it) 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
EP1832295A1 (en) 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
CA2649063C (en) 2006-05-02 2014-11-25 Luigina Romani Use of thymosin .alpha.1, alone or in combination with ptx3 or ganciclovir, for the treatment of cytomegalovirus infection

Also Published As

Publication number Publication date
CA2563400C (en) 2013-07-30
MXPA06012889A (es) 2007-02-15
JP5574565B2 (ja) 2014-08-20
TW200602075A (en) 2006-01-16
CN1950104B (zh) 2010-11-10
SI1750744T1 (sl) 2008-10-31
RS50591B (sr) 2010-05-07
CA2563400A1 (en) 2005-11-17
ITRM20040223A1 (it) 2004-08-07
TWI393569B (zh) 2013-04-21
US20140296135A1 (en) 2014-10-02
DK1750744T3 (da) 2008-09-29
AU2005239913A1 (en) 2005-11-17
ME02743B (me) 2010-05-07
CN1950104A (zh) 2007-04-18
DE602005007485D1 (de) 2008-07-24
KR101192611B1 (ko) 2012-10-18
KR20070007375A (ko) 2007-01-15
HK1103961A1 (en) 2008-01-04
HRP20080413T3 (en) 2008-10-31
ATE397937T1 (de) 2008-07-15
ES2306145T3 (es) 2008-11-01
BRPI0510718A (pt) 2007-11-20
EP1750744A1 (en) 2007-02-14
WO2005107791A1 (en) 2005-11-17
PT1750744E (pt) 2008-08-14
US20080026997A1 (en) 2008-01-31
CY1108332T1 (el) 2014-02-12
US8778389B2 (en) 2014-07-15
AU2005239913B2 (en) 2011-08-18
EP1750744B1 (en) 2008-06-11
PL1750744T3 (pl) 2008-11-28
JP2007536380A (ja) 2007-12-13

Similar Documents

Publication Publication Date Title
DOP2019000185A (es) Una formulación sólida de dosificación farmacéutica
PL2178504T3 (pl) Roztwór oczny na bazie prostagladyn bez środka konserwującego
CL2019000586A1 (es) Composiciones de toxinas clostridiales no proteicas.
CL2007002594A1 (es) Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. .
UA93903C2 (ru) Производные тетрагидроизохинолина для повышения функции памяти
BRPI0505524A (pt) método passìvel de utilização com um poço subterráneo, sistema passìvel de utilização com um poço subterráneo, e ferramenta passìvel de utilização com um poço subterráneo
CL2008001498A1 (es) Uso de un anticuerpo contra el factor d en la prevencion o tratamiento de una condicion ocular asociada al complemento.
CR11339A (es) Combinaciones que comprenden una cepa fungicida y un compuesto activo
MX2019006428A (es) Composiciones antitranspirantes/desodorantes libres de aluminio.
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
UA85574C2 (uk) Ендопаразитоцидний засіб для місцевого застосування
CL2007003722A1 (es) Compuestos derivados de propionamida n-sustituida por heterociclo, activadores de glucoquinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento o prevencion de la diabetes.
CY1108332T1 (el) Φαρμακο για τη θεραπεια μυκητιακων λοιμωξεων, ειδικοτερα της ασπεργιλλωσης
MX385380B (es) Formulacion topica para promover la curacion de heridas.
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
CL2007002026A1 (es) Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.
AR061552A1 (es) Tapones punctales para el suministro de agentes activos
BRPI0509053A (pt) composição farmacêutica anidra e uso de um agente siliconado e de uma composição
CO6551744A2 (es) Combinación de fármacos con teobromina y su uso en terapia
ECSP12011892A (es) Combinación de fármacos con teobromina y su uso en terapia
MX2020010424A (es) Comprimido o composicion que contiene n-acil etanolamina y cannabinoides.
WO2019059722A3 (ko) 부분 비만 치료용 조성물 및 이를 포함하는 마이크로니들
MX2021000771A (es) Formulacion aerosolizable.
PT1713438E (pt) Sabonete medicinal
IT201700116889A1 (it) Dispositivo nebulizzatore di un fluido per la cura e/o la protezione della pelle, in particolare di principi attivi.

Legal Events

Date Code Title Description
FB Suspension of granting procedure